You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Version: 1 Jun 2018
Type of Content: Drug Safety, Guidelines & Advice, Clinical
Document Status: Current
CCO Systemic Treatment

Guideline Objective

The Systemic Treatment Program would like to raise awareness of potential safety concerns and mitigation strategies shared by provinces who have adopted the subcutaneous rituximab formulation.

Intended Guideline Users

Providers (Physicians, Pharmacists, Nurses)

pdf download Full Report (PDF) (342.98 KB)